PF-04217903, also known as PF4217903, is a small molecule inhibitor of the fibroblast growth factor receptor (FGFR) pathway. It is currently being studied as a potential treatment for various types of cancers, including breast cancer, lung cancer, and gastric cancer. PF-04217903 was first developed by Pfizer and has undergone several clinical trials.
The chemical name of PF-04217903 is 4-(4-(4-(pyridin-2-yl)piperazin-1-yl)quinolin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-amine.
The molecular formula of PF-04217903 is C26H30N8O.
The formula weight of PF-04217903 is 466.58 g/mol.
The CAS number of PF-04217903 is 956905-27-4.
Top Ten Keywords from Google and Synonyms
Synonyms: PF-4217903, PF4217903, 4-(4-(4-Pyridin-2-ylpiperazin-1-yl)quinolin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-amine
Health Benefits of PF-04217903
PF-04217903 has shown promising results in treating various types of cancers, particularly breast cancer, lung cancer, and gastric cancer. By inhibiting the FGFR pathway, it works to slow or stop the growth and spread of cancer cells.
Clinical studies have shown that PF-04217903 can effectively treat breast cancer, lung cancer, and gastric cancer. In one phase I study, researchers found that PF-04217903 was well-tolerated and showed signs of efficacy in patients with advanced solid tumors who had previously received other treatments.
PF-04217903 works by specifically targeting the FGFR pathway, which is often overactive in cancer cells and plays a critical role in regulating cell growth and survival. By inhibiting this pathway, PF-04217903 suppresses the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
PF-04217903 has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, and diarrhea. More severe side effects may occur in some patients, such as liver damage or allergic reactions. Patients should be closely monitored for any adverse reactions while taking PF-04217903.
The most common side effects of PF-04217903 include:
More severe side effects may occur in some patients, such as:
The dosing of PF-04217903 depends on the type of cancer being treated and other individual factors. It is typically administered orally in tablet form, either alone or in combination with other cancer therapies. The recommended dose varies depending on the clinical trial or physician's discretion.
In conclusion, PF-04217903 is a promising drug candidate for cancer therapy, particularly in the treatment of various types of cancers, including breast cancer, lung cancer, and gastric cancer. By inhibiting the FGFR pathway, it shows potential in suppressing the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression. While further clinical trials are needed to determine its efficacy and safety, PF-04217903 represents an important step towards precision medicine and molecular targeted therapy in cancer treatment.